OPHTHETIC- proparacaine hydrochloride solution
OPHTHETIC® (proparacaine HCI ophthalmic solution) 0.5% is a topical local anesthetic for ophthalmic use.
Benzoic acid, 3-amino-4-propoxy-, 2-(diethylamino)ethyl ester, monohydrochloride.
Contains: Active: proparacaine HCl 0.5%. Preservative: benzalkonium chloride (0.01%). Inactives: glycerin; purified water; sodium chloride; and hydrochloric acid and/or sodium hydroxide to adjust pH (5.0 to 6.0).
OPHTHETIC® ophthalmic solution is a rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes.
OPHTHETIC® ophthalmic solution is indicated for procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g., tonometry, gonioscopy, removal of corneal foreign bodies, and for short corneal and conjunctival procedures.
OPHTHETIC® ophthalmic solution should be considered contraindicated in patients with known hypersensitivity to any of the ingredients of this preparation.
Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.
Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females.
Animal reproduction studies have not been conducted with OPHTHETIC® (proparacaine hydrochloride ophthalmic solution) 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to a nursing mother.
Safety and effectiveness of proparacaine HCl ophthalmic solution in pediatric patients have been established. Use of proparacaine HCl is supported by evidence from adequate and well-controlled studies in adults and children over the age of twelve, and safety information in neonates and other pediatric patients.
No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.
Occasional temporary stinging, burning and conjunctival redness may occur with the use of proparacaine. A rare, severe, immediate-type, apparently hyperallergic corneal reaction, characterized by acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and, sometimes, iritis with descemetitis has been reported.
Allergic contact dermatitis from proparacaine with drying and fissuring of the fingertips has also been reported.
Usual Dosage: Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating.
Short corneal and conjunctival procedures: 1 drop in each eye every 5 to 10 minutes for 5 to 7 doses.
Note: OPHTHETIC® should be clear to straw-color. If the solution becomes darker, discard the solution.
OPHTHETIC® (proparacaine HCI ophthalmic solution) 0.5% is supplied sterile in opaque natural LDPE plastic bottles with dropper tips and white high impact polystyrene (HIPS) caps as follows:
15 mL in 15 mL bottle — NDC 11980-048-15
Bottle must be stored in unit carton to protect contents from light. Store bottles under refrigeration at 2° to 8°C (36° to 46°F).
© 2004 Allergan, Inc.
Irvine, CA 92612, U.S.A.
® Marks owned by Allergan, Inc.
| OPHTHETIC |
proparacaine hydrochloride solution
|Labeler — Allergan, Inc.|
Revised: 04/2006 Allergan, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.